Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;121(6):756-766.
doi: 10.1007/s12185-025-03989-z. Epub 2025 Apr 27.

Disease response criteria in Langerhans cell histiocytosis: a global view

Ilia N Buhtoiarov  1 , Milen Minkov  2 , Reza Vali  3 , Oussama Abla  4
Affiliations
Review

Disease response criteria in Langerhans cell histiocytosis: a global view

Ilia N Buhtoiarov et al. Int J Hematol. 2025 Jun.

Abstract

Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm with heterogeneous presentations. The discovery of BRAFV600E and other MAPK pathway mutations drastically transformed the treatment landscape, especially for high-risk LCH and CNS-LCH. While treatment strategies for children and adults are somewhat similar, response assessment methodologies remain highly dichotomized.Currently, separate treatment response criteria exist for children and adults, especially in therapeutic trials. Considering the rapid evolution of targeted MAPK-inhibitor therapies, along with ultrasensitive detection of minimal residual disease biomarkers (e.g., circulating BRAFV600E-encoding DNA) and sophisticated imaging tools (18F-FDG-PET and whole-body MRI), harmonization of response criteria in LCH is clearly warranted. The Histiocyte Society Global LCH Treatment Response Harmonization Task Force, a collaborative network of pediatric and adult LCH experts, is set to propose updated pediatric LCH treatment response criteria, which will also serve as the foundation for a universal response assessment tool for pediatric and adult LCH. In this review, we focus on the past, present, and likely future of response assessment in LCH patients, and discuss needs that remain unmet in the targeted therapy era.

Keywords: Harmonization; Langerhans cell histiocytosis; Response; Therapy.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: None.

References

    1. Abla O. Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease. Hematology Am Soc Hematol Educ Program. 2023;2023(1):386–95. - PMC - PubMed
    1. Buhtoiarov IN, Mukherjee S, Radivoyevitch T. Incidence, Clinical Features, and Outcomes of Langerhans Cell Histiocytosis in the United States. J Pediatr Hematol Oncol. 2022;44(7):e1006–15. - PubMed
    1. Allen CE, Merad M, McClain KL. Langerhans Cell Histiocytosis. N Engl J Med. 2018;379(9):856–68. - PMC - PubMed
    1. Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–98. - PubMed
    1. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135(16):1319–31. - PubMed

LinkOut - more resources